Trial Profile
A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Ofatumumab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms RESONATE
- Sponsors Janssen; Pharmacyclics
- 15 Jun 2023 Results evaluating the outcomes of Brutons tyrosine kinase inhibitor (BTKi) treatment in patients with R/R CLL by comparing the efficacy of ibrutinib in RESONATE to ALPINE and ELEVATE-RR, using a matching adjusted indirect comparison (MAIC) analysis. , presented at the 28th Congress of the European Haematology Association
- 14 Jun 2023 Results assessing frequency and time to detection of BTK and PLCG2 mutations in peripheral blood samples across 5 clinical trials (NCT01500733, NCT01578707, NCT01722487, NCT01744691 and NCT02264574) published in the Clinical Cancer Research
- 08 Dec 2020 Results from (RESONATE-2, iLLUMINATE, NCT01500733, RESONATE and RESONATE-17) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology